Abstract 576: ABO Blood Group and Platelet Aggregation
Background: ABO blood groups have been linked to coronary thrombosis, with non-O blood groups at higher risk of thrombosis. ABO blood group antigens are expressed on platelet glycoproteins, including the IIb fibrinogen receptor, and may affect platelet function via glycan modifications. We hypothesized that non-O blood groups would demonstrate higher levels of platelet aggregation compared to type O blood group.
Methods: Healthy, non-smoking subjects were recruited to a protocol investigating glycan modification of platelets. Ex vivo platelet aggregation was assessed by light transmission aggregometry of platelet-rich plasma in dose-response to collagen (0.04-0.2 mg/mL) and thrombin receptor activating peptide (TRAP) (1-5 μmol). Maximal platelet aggregation data, aggregation rate and lag time were compared at each concentration across blood groups A, B, AB and O by ANOVA testing.
Results: A total of 91 subjects were recruited (ABO types; 32 A, 16 B, 8 AB, 35 O). The average age of the subjects was 31 years, 58% were Caucasian and 61% were female. There were no significant differences in age, race and gender between ABO blood groups. For collagen concentrations ranging from 0.04-0.2 mg/mL, there was no significant difference in mean platelet aggregation, rate of aggregation and lag time between blood groups. For TRAP concentrations between 1-5 μmol, there was also no significant difference in mean platelet aggregation and rate of aggregation between blood groups. For TRAP at 2 μmol and 3 μmol, blood group AB demonstrated a longer lag time compared to blood groups A, B, and O (TRAP 2 μmol; 13 sec type AB vs 5.21 sec type A, 4.18 sec type B, 3.57 sec type O, TRAP 3 μmol; 9.12 sec type AB vs 3.34 sec type A, 4.31 sec type B, 2.65 sec type O) but these secondary analyses were of marginal significance after consideration of multiple testing.
Conclusion: These data for ex vivo platelet aggregation dose-response to collagen and TRAP do not support significant differences in platelet function by ABO blood type. Further studies with larger sample sizes and of specific platelet glycoprotein functions are required to address potential subtle influences of ABO glycans on platelet reactivity.
Author Disclosures: M. Zhong: None. K. Terembula: None. A. Tsai: None. H. Zhang: None. S. Kapoor: None. M.P. Reilly: None.
- © 2014 by American Heart Association, Inc.